Tuesday, July 15, 2025 | 03:01 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Alembic Pharmaceuticals

Alembic Pharmaceuticals up 2% as arm acquires Utility Therapeutics; details

Alembic Pharmaceuticals share price rose after the company announced that its wholly-owned subsidiary, Alembic Pharmaceuticals Inc., has acquired Utility Therapeutics Ltd. for approximately $12 mn

Alembic Pharmaceuticals up 2% as arm acquires Utility Therapeutics; details
Updated On : 03 Jul 2025 | 11:16 AM IST

Alembic Pharma gets USFDA nod for generic cancer treatment injection

Alembic Pharmaceuticals on Monday said it has received the final approval from the US health regulator for its generic Doxorubicin Hydrochloride Liposome injection in different types of cancer. The approval by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) is for Doxorubicin Hydrochloride Liposome injection of strengths 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) single-dose vials, Alembic Pharmaceuticals said in a statement. The approved ANDA is therapeutically equivalent to the reference-listed drug product (RLD), Doxil Liposome Injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL), of Baxter Healthcare Corporation, it added. Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of ovarian Cancer, AIDS-Related Kaposi's sarcoma, and multiple myeloma, the company said. Citing IQVIA data, Alembic said Doxorubicin Hydrochloride Liposome injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2mg/mL) single-dose ...

Alembic Pharma gets USFDA nod for generic cancer treatment injection
Updated On : 30 Jun 2025 | 1:07 PM IST

Why is Alembic Pharmaceuticals' share in demand today? Key details here

Alembic Pharmaceuticals share surged after the company received final approval from the USFDA for its ANDA for Doxorubicin Hydrochloride Liposome Injection in two dosage strength.

Why is Alembic Pharmaceuticals' share in demand today? Key details here
Updated On : 30 Jun 2025 | 12:22 PM IST

Alembic Pharma receives USFDA approval for generic hypertension drug

Alembic Pharmaceuticals on Friday said it has received final approval from the US health regulator for its generic version of amlodipine and atorvastatin tablets, used to treat high blood pressure. The final approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Amlodipine and Atorvastatin tablets of strengths 2.5 mg/10 mg, 2.5 mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg, the company said in a statement. These are therapeutically equivalent to the reference-listed drug product, Caduet tablets of corresponding strengths of Pharmacia and Upjohn Co LLC, it added. Alembic said it has a cumulative total of 223 ANDA approvals (199 final approvals and 24 tentative approvals) from the USFDA.

Alembic Pharma receives USFDA approval for generic hypertension drug
Updated On : 23 May 2025 | 3:13 PM IST

Alembic Pharma Q4 profit dips 12%, revenue rises 17% to Rs 1,770 cr

India branded business grows 8% in Q4FY25 with 4 product launches while Ex-US markets rise 43% and US segment delivers 20% growth during the quarter

Alembic Pharma Q4 profit dips 12%, revenue rises 17% to Rs 1,770 cr
Updated On : 06 May 2025 | 4:41 PM IST

Alembic Pharma down 3% on getting USFDA observation for its Vadodara plant

The filing further read the company will provide a comprehensive response to US FDA for the observations within the stipulated period

Alembic Pharma down 3% on getting USFDA observation for its Vadodara plant
Updated On : 10 Mar 2025 | 9:59 AM IST

Alembic Pharma Q3 results: PAT falls 23.29% amid market headwinds

Alembic's revenue from operations rose to Rs 1,692.74 crore in Q3FY25, a 3.8 per cent Y-o-Y increase from Rs 1,630.57 crore in Q3FY24

Alembic Pharma Q3 results: PAT falls 23.29% amid market headwinds
Updated On : 03 Feb 2025 | 8:11 PM IST

Alembic Pharma Q3 result: Profit dips 23% to Rs 138 cr on weak sales

A significant chunk of revenue for most Indian generic drugmaker comes from the U.S. and fierce competition in the North American market has weighed on domestic firms' margins

Alembic Pharma Q3 result: Profit dips 23% to Rs 138 cr on weak sales
Updated On : 03 Feb 2025 | 4:06 PM IST

Stocks to sell on rise: Apollo Tyres, Cyient may fall upto 34%, show charts

Metropolis Healthcare, Alembic Pharma and Tejas Networks are the other 3 stocks to witness a 'Death Cross' on the chart in recent days; technically this is a negative development for these stocks.

Stocks to sell on rise: Apollo Tyres, Cyient may fall upto 34%, show charts
Updated On : 31 Jan 2025 | 1:00 PM IST

Here's why Alembic Pharma was buzzing in trade on December 20, details here

Alembic Pharma share rose after the company announced that it has received final approval from the USFDA for its ANDA Divalproex Sodium Delayed-Release Capsules USP, 125 mg

Here's why Alembic Pharma was buzzing in trade on December 20, details here
Updated On : 20 Dec 2024 | 2:09 PM IST

Alembic Pharma gets tentative USFDA nod for Olopatadine drug; stock up 2%

Alembic has a cumulative total of 219 ANDA approvals (192 final approvals and 27 tentative approvals) from the USFDA

Alembic Pharma gets tentative USFDA nod for Olopatadine drug; stock up 2%
Updated On : 04 Dec 2024 | 2:54 PM IST

Nifty Pharma jumps over 2%: Analysts decode the drivers behind the rally

Individually, Cipla soared up to 3.68 per cent to hit an intraday high of Rs 1,547.70 per share, while Sun Pharma soared up to 3.30 per cent to hit an intraday high of Rs 1,791.60 per share

Nifty Pharma jumps over 2%: Analysts decode the drivers behind the rally
Updated On : 29 Nov 2024 | 12:52 PM IST

Alembic Pharma share price gains 5% after USFDA okays seizures drug

Alembic Pharma share price surged after the United States Food and Drug Administration (USFDA) gave final approval for Lamotrigine ExtendedRelease Tablets USP, 200 mg, 250 mg, and 300 mg.

Alembic Pharma share price gains 5% after USFDA okays seizures drug
Updated On : 03 Oct 2024 | 12:27 PM IST

What drove this pharmaceutical stock's 4% increase today? Find out here!

Alembic Pharma share price surged after the USFDA issued establishment inspection report (EIR) for the inspection carried out at the company's Oral Solid Formulation Facility (F-I).

What drove this pharmaceutical stock's 4% increase today? Find out here!
Updated On : 30 Sep 2024 | 11:34 AM IST

Alembic Pharma shares jump 5% after USFDA approval; check details here

Alembic Pharma share price surged up to 5 per cent at Rs 1,170.60 per share on the BSE in Thursday's intraday trade

Alembic Pharma shares  jump 5% after USFDA approval; check details here
Updated On : 05 Sep 2024 | 2:19 PM IST

Alembic Pharma shares rise after USFDA drug approval; check details here

Shares of Alembic Pharmaceuticals soared up to 4.13 per cent at Rs 1,135 per share on the BSE

Alembic Pharma shares rise after USFDA drug approval; check details here
Updated On : 27 Aug 2024 | 10:45 AM IST

Here's why Alembic Pharma stock skyrocketed 12% on August 26; details here

The surge in Alembic Pharma share price came after the company announced that it has received US Food & Drug Administration (USFDA) final approval for Betamethasone Valerate Foam, 0.12 per cent.

Here's why Alembic Pharma stock skyrocketed 12% on August 26; details here
Updated On : 26 Aug 2024 | 11:23 AM IST

Alembic Pharma gets approval from US FDA to market generic medication

Alembic Pharmaceuticals on Tuesday said it has received approval from the US health regulator to market a generic product indicated for prophylaxis of deep vein thrombosis. The company has received approval from the US Food and Drug Administration (USFDA) to market Dabigatran Etexilate Capsules (110 mg), the drug firm said in a regulatory filing. Dabigatran Etexilate Capsules are indicated for prophylaxis of deep vein thrombosis and pulmonary embolism following hip replacement surgery. The approved product is therapeutically equivalent to Boehringer Ingelheim Pharmaceuticals Inc's Pradaxa Capsules (110 mg). The company said it now has a cumulative total of 211 ANDA (abbreviated new drug application) approvals from the USFDA. Shares of the company on Tuesday closed 3.17 per cent down at Rs 1,076 apiece on the BSE.

Alembic Pharma gets approval from US FDA to market generic medication
Updated On : 13 Aug 2024 | 5:17 PM IST

Alembic Pharma posts 11.5% growth in profit, driven by US business

For the quarter, the India Branded Business segment saw a 9 per cent growth, reaching Rs 572 crore

Alembic Pharma posts 11.5% growth in profit, driven by US business
Updated On : 08 Aug 2024 | 6:53 PM IST

Alembic Pharma Q1FY25 results: Net profit increases 12% to Rs 135 cr

Alembic Pharmaceuticals on Thursday said its consolidated net profit increased by 12 per cent to Rs 135 crore for the first quarter ended on June 30, 2024. The drug firm had reported a net profit of Rs 121 crore for the April-June quarter of last fiscal. Total income increased to Rs 1,564 crore for the June quarter as against Rs 1,498 crore in the year-ago period, Alembic Pharmaceuticals said in a regulatory filing. "India branded business continues to work on improving the execution ability both in quality and scale," Alembic Pharmaceuticals MD Shaunak Amin said. The specialty and animal health segment witnessed robust growth, he added. "The USFDA conducted an audit at our formulation facility F1, without any observations, underscoring our dedication to compliance and quality. The US business grew by 18 per cent during the quarter," Amin said. Shares of the company ended 0.11 per cent down at Rs 1,218.65 apiece on the BSE.

Alembic Pharma Q1FY25 results: Net profit increases 12% to Rs 135 cr
Updated On : 08 Aug 2024 | 4:17 PM IST